Saxsons Group

Gold Anchor™ — what the literature says.

22 peer-reviewed studies across 4 clinical indications. Each card distils the comparative result so you can see, in seconds, where Gold Anchor stands against the alternative.

0.32% migration rate (5-yr, n=795)
95.5% MRI-only fiducial detection
22 peer-reviewed publications
Product specs Clinical guide

Jump to a clinical site

Prostate IGRT 8 papers Liver SBRT 3 papers Lung SBRT 3 papers Particle Therapy 4 papers
Filter
Patients with intrafraction position shifts
Patients with shifts
77%
Fractions corrected
17%
Missed w/o fiducials
100%
Prostate 2025
77% patients had intrafraction shifts — all detectable with Gold Anchor kV imaging

Online correction of intrafraction motion during VMAT for prostate radiotherapy using fiducial-based kV imaging

Journal of Applied Clinical Medical Physics

Simulation time: conventional vs MRI-only
Baseline
Conventional CT sim
CT scan + MRI required
vs
−7.1 days
Gold Anchor MRI-only
95.5% fiducial detection
Prostate 2025
95.5% MRI fiducial detection · −7.1 days simulation time

MRI-only planning workflow with deep learning synthetic CT for prostate EBRT using Gold Anchor fiducials

Journal of Applied Clinical Medical Physics (Deng et al.)

Fiducial marker migration rate
Gold Anchor™
0.32%
Coil fiducials
19%
Cylindrical gold
46.9%
Prostate 2023
0.32% 795 patients · zero migration during radiotherapy

Intra-prostatic Gold Anchor Fiducial Marker Insertion: Five-Year Institutional Experience

BMC Medical Imaging

Fluoroscopic frame detection rate
Gold Anchor™ (non-std shape)
100%
Round markers (reference)
98%
Prostate 2024
Real-time fluoroscopic tracking validated — 100% frame detection rate

Real-time tracking of Gold Anchor markers on X-ray fluoroscopic images for prostate radiotherapy

Physics in Medicine & Biology (Sakata et al.)

vs competing fiducial systems
↓
Treatment cost
↑
QALYs gained
=
Complications
Dominant strategy — wins on cost and outcome
Prostate 2020
Dominant lower cost AND higher QALYs — health-economic optimal choice

Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer IGRT

Cureus (Lundqvist & Levin)

DWI image quality preserved
Gold Anchor (in situ)
~98%
Titanium markers
71%
Prostate 2021
Minimal DWI artefact — does not degrade diffusion-weighted imaging

Effect of gold fiducial markers on diffusion-weighted MRI in prostate radiotherapy

Asia Pacific Journal of Clinical Oncology

Safety outcomes across 621 patients
0.3%
UTI rate
0
Sepsis cases
0
Hospitalisations
Safest published transrectal implantation series
Prostate 2018
0.3% 621 patients · zero sepsis · zero hospitalisations

Low Infection Rate After Transrectal Implantation of Gold Anchor Fiducial Markers in Prostate

PMC / Radiation Oncology

Evidence level
RCT
Evidence class
I-A
GRADE strength
n=?
Prospective
Highest-grade evidence — randomized controlled trial
Prostate 2023
RCT prospective randomized proton therapy trial — Gold Anchor image guidance validated

Proton therapy planning and image-guidance strategies within a randomized controlled trial for high-risk prostate cancer

Clinical and Translational Radiation Oncology

Mean positioning error (mm)
5.3 mm
CBCT soft-tissue only
Without fiducials
vs
1.5 mm
Gold Anchor fiducials
3.5× more accurate
Liver 2023
1.5 mm with fiducials vs 5.3 mm without — 3.5× reduction

Fiducial Markers Allow Accurate and Reproducible Delivery of Liver SBRT

Current Oncology (Moskalenko et al.)

SyncTraX gating with Gold Anchor
✓
Real-time tracking
✓
Isocenter shift
0
Migration events
Only folding fiducial validated for SyncTraX
Liver 2023
Real-time gated delivery with Gold Anchor — isocenter shift validated

Real-time tumour-tracking radiotherapy with SyncTraX for primary liver tumours

Journal of Radiation Research

Marker visibility after 30 days
Gold Anchor™
100%
Coil marker
82%
Cylindrical rod
71%
Liver 2017
3 types comparative study — Gold Anchor best on migration and visibility

Percutaneous Ultrasound-Guided Fiducial Marker Placement for Liver Cancer Robotic Stereotactic Radiosurgery

Arab Journal of Gastroenterology (Marsico et al.)

Marker visibility over full IGRT course
Gold Anchor (NSCLC, n=24)
100%
Standard coil markers
81%
Lung 2018
Long-term full NSCLC course — 100% marker visibility maintained

Long-term safety and visibility of a novel fiducial marker for NSCLC IGRT

Clinical and Translational Radiation Oncology (de Blanck et al.)

CT artefact volume (relative)
Gold Anchor™ (folding)
Minimal
Standard gold cylinder
Low
Platinum-iridium coil
Moderate
Lung 2023
CT + CK minimal CT artefact · CyberKnife Synchrony recognition validated

CT metal artifact and CyberKnife fiducial recognition for novel Gold Anchor markers

Journal of Applied Clinical Medical Physics

Access compared to standard fiducials
22G
Needle gauge
✓
Central lesions
✓
Bronchoscopic
3× thinner than standard bronchoscopic fiducials
Lung 2021
22G EUS needle — central and mediastinal lesions accessible

Endoscopic Gold Anchor placement for central lung tumours via 22G EUS needle

Journal of Radiation Research

Proton therapy implementation
✓
Gating validated
✓
QA protocol
✓
MRI compatible
First commissioned real-time gated proton protocol with Gold Anchor
Particle 2024
Commissioned full proton gating QA protocol validated — clinical implementation

Real-time gated proton therapy with reduced source-to-imager distance: Commissioning and QA

Physica Medica

Setup error comparison
High error
Without fiducials
Soft-tissue only
vs
↓ Significant
Gold Anchor
Intra + inter-fraction
Particle 2024
↓ Error setup error and motion both significantly reduced with fiducials

Inter-fractional error and intra-fractional motion with vs without fiducials in carbon-ion radiotherapy

Radiological Physics and Technology

Proton fluence perturbation
Gold Anchor™ (folding)
3.1%
Gold cylinder (1 mm)
8.2%
Titanium fiducials
12.4%
Particle 2022
3.1% proton fluence perturbation — lowest among metallic fiducials

Comparison of fiducial markers for proton therapy: imaging and proton fluence perturbations

Frontiers in Oncology

Clinical trial evidence
RCT
Study design
High
Risk prostate
P+
Proton therapy
Only fiducial in a proton therapy randomized trial
Particle 2023
RCT Gold Anchor used in prospective randomized proton therapy trial

Proton therapy planning and image-guidance within a randomized controlled trial for high-risk prostate cancer

Clinical and Translational Radiation Oncology

MRI detection rate (rectal IGRT)
Gold Anchor™
97%
Surgical clips
68%
Other sites 2019
MRI+ validated for rectal cancer IGRT — MRI and kV visible

MRI Visibility of Gold Fiducial Markers for Image-Guided Radiotherapy of Rectal Cancer

Radiotherapy & Oncology

Bladder wall implantation outcomes
100%
Retention rate
0
Complications
✓
CBCT visible
Endoscopic approach — no percutaneous puncture needed
Other sites 2014
Feasible endoscopic bladder-wall placement — 100% marker retention

Endoscopic Gold Fiducial Marker Placement for Muscle-Invasive Bladder Cancer IGRT

PLoS One

Marker position stability over treatment
Gold Anchor (intracavitary)
100%
Standard applicator clips
74%
Other sites 2013
Stable intracavitary markers stable for full gynecologic RT course

Intracavitary fiducial gold marker placement for image-guided radiotherapy of gynecological cancers

Acta Oncologica

Gynaecologic IGRT with Gold Anchor
✓
Cervical Ca
✓
Endometrial
✓
MRI + kV vis.
Multi-site gynecologic validation
Other sites 2020
IGRT cervical and endometrial cancer — intrafraction guidance validated

Gold fiducial marker implantation for image-guided radiotherapy in cervical and endometrial cancer

Journal of Contemporary Brachytherapy

Back to Radiotherapy products

White Papers & Background Reading

Longer-form papers on Gold Anchor across MR-only workflows, proton therapy and comparative imaging — companions to the peer-reviewed evidence above.

PDF

Marker comparison

Head-to-head against coil, cylindrical and titanium fiducials — migration, visibility, artefact.

243 KB Download
PDF

MR+ marker — MRI visibility white paper

Material whitepaper on the MR+ variant designed for MR-only planning workflows.

2.6 MB Download
PDF

MR-only workflow — Tampere white paper

Clinical experience with MR-only prostate SBRT planning using Gold Anchor MR+.

353 KB Download
PDF

Superior IGRT for prostate SBRT

Why Gold Anchor outperforms alternatives in prostate stereotactic body radiotherapy.

248 KB Download
PDF

Gold Anchor for proton therapy

PTCOG paper — fluence perturbation, imaging and image-guidance in proton centres.

1.9 MB Download
PDF

Marker implantation trends

Global trends in fiducial implantation practice across modern radiotherapy.

108 KB Download
PDF

Why use fiducial markers?

Educational primer for new users — the case for marker-based IGRT.

1.7 MB Download

Educational & Background Videos

Background and storytelling content. Implantation demos and customer testimonials live on the product page.

Gold Anchor™

More for this product

Each card opens a focused post for a specific specialty — clinical workflow and evidence, written for the persona you select.

For Radiation Oncologist

Radiation Oncologist

Intrafraction motion in prostate SBRT

Conventional coil and cylindrical fiducials migrate up to 19–47 %. Can a 0.32 % migration rate change how prostate SBRT is planned?

Read this Radiation Oncologist

Respiratory motion in liver SBRT

When the target moves with every breath, what does it take to get from 5.3 mm soft-tissue alignment error down to 1.5 mm?

Read this Radiation Oncologist

Coil marker migration in lung SBRT

Roughly one in five standard coil markers migrate in lung parenchyma. What changes with a fold-anchor design and a thinner needle?

Read this Radiation Oncologist

Particle-therapy beam compatibility

What is the proton-fluence perturbation at clinical energies — and how do Gold Anchor fiducials compare to gold cylinders and titanium markers?

Read this Radiation Oncologist

Clinical evidence — across organ sites

A single-page overview of where the published evidence sits for prostate, liver, lung and particle therapy.

Read this